116 related articles for article (PubMed ID: 38062999)
21. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
22. Machine learning identification of cuproptosis and necroptosis-associated molecular subtypes to aid in prognosis assessment and immunotherapy response prediction in low-grade glioma.
Miao Y; Liu J; Liu X; Yuan Q; Li H; Zhang Y; Zhan Y; Feng X
Front Genet; 2022; 13():951239. PubMed ID: 36186436
[TBL] [Abstract][Full Text] [Related]
23. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
24. Identification of Critical m
Zheng J; Wang X; Qiu Y; Wang M; Yu H; Zhou Z; Wu Z; Jiang X
Biomed Res Int; 2021; 2021():9959212. PubMed ID: 34212046
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance and molecular annotation of cellular morphometric subtypes in lower-grade gliomas discovered by machine learning.
Liu XP; Jin X; Seyed Ahmadian S; Yang X; Tian SF; Cai YX; Chawla K; Snijders AM; Xia Y; van Diest PJ; Weiss WA; Mao JH; Li ZQ; Vogel H; Chang H
Neuro Oncol; 2023 Jan; 25(1):68-81. PubMed ID: 35716369
[TBL] [Abstract][Full Text] [Related]
26. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
[TBL] [Abstract][Full Text] [Related]
27. Screening TCGA database for prognostic genes in lower grade glioma microenvironment.
Ni J; Liu S; Qi F; Li X; Yu S; Feng J; Zheng Y
Ann Transl Med; 2020 Mar; 8(5):209. PubMed ID: 32309356
[TBL] [Abstract][Full Text] [Related]
28. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
[TBL] [Abstract][Full Text] [Related]
29. The promising novel biomarkers and candidate small molecule drugs in lower-grade glioma: Evidence from bioinformatics analysis of high-throughput data.
Zhang B; Wu Q; Xu R; Hu X; Sun Y; Wang Q; Ju F; Ren S; Zhang C; Qi F; Ma Q; Wang Z; Zhou YL
J Cell Biochem; 2019 Sep; 120(9):15106-15118. PubMed ID: 31020692
[TBL] [Abstract][Full Text] [Related]
30. Genome-wide analyses of the prognosis-related mRNA alternative splicing landscape and novel splicing factors based on large-scale low grade glioma cohort.
Liu WR; Li CY; Xu WH; Liu XJ; Tang HD; Huang HN
Aging (Albany NY); 2020 Jul; 12(13):13684-13700. PubMed ID: 32658870
[TBL] [Abstract][Full Text] [Related]
31. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
32. Radiogenomics correlation between MR imaging features and mRNA-based subtypes in lower-grade glioma.
Liu Z; Zhang J
BMC Neurol; 2020 Jun; 20(1):259. PubMed ID: 32600353
[TBL] [Abstract][Full Text] [Related]
33. Elucidating the Role of Pyroptosis in Lower-Grade Glioma: Development of a Novel Scoring System to Enhance Personalized Therapeutic Approaches.
Chen X; Xu Y; Wang M; Ren C
J Mol Neurosci; 2023 Aug; 73(7-8):649-663. PubMed ID: 37566191
[TBL] [Abstract][Full Text] [Related]
34. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
35. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
36. Exploring the Correlation of Abnormal CXCL9 Expression with Immune Infiltration in Glioma and Patient Prognosis Based on TCGA and GTEx Databases.
Liao Y; Liu B; Jin C; Liao X; Zhang Z
J Mol Neurosci; 2022 Dec; 72(12):2413-2424. PubMed ID: 36449138
[TBL] [Abstract][Full Text] [Related]
37. Identification and verification of the ferroptosis- and pyroptosis-associated prognostic signature for low-grade glioma.
Wang J; Ren J; Liu J; Zhang L; Yuan Q; Dong B
Bosn J Basic Med Sci; 2022 Sep; 22(5):728-750. PubMed ID: 35276059
[TBL] [Abstract][Full Text] [Related]
38. Study on the Prognostic Values of Dynactin Genes in Low-Grade Glioma.
Su X; Li H; Chen S; Qin C
Technol Cancer Res Treat; 2021; 20():15330338211010143. PubMed ID: 33896271
[TBL] [Abstract][Full Text] [Related]
39. An integrative multi-omics analysis based on liquid-liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature.
Zheng J; Wu Z; Qiu Y; Wang X; Jiang X
J Transl Med; 2022 Jan; 20(1):55. PubMed ID: 35093128
[TBL] [Abstract][Full Text] [Related]
40. Development of a nomogram for prognostic prediction of lower-grade glioma based on alternative splicing signatures.
Wang Y; Wang Z; Zhao B; Chen W; Wang Y; Ma W
Cancer Med; 2020 Dec; 9(24):9266-9281. PubMed ID: 33047900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
